PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10713399-4	2000	We examined the effect of retigabine on KCNQ2/3 expressed in Chinese hamster ovary cells.	ezogabine	26-36	potassium voltage-gated channel subfamily KQT member 2	Cricetulus griseus	40-45	
12702739-0	2003	Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells.	ezogabine	44-54	potassium voltage-gated channel subfamily KQT member 2	Cricetulus griseus	65-70	
10953053-5	2000	Retigabine (0.1 to 10 microM) induced a potassium current and hyperpolarized CHO cells expressing KCNQ2/Q3 cells but not in wild-type cells.	ezogabine	0-10	potassium voltage-gated channel subfamily KQT member 2	Cricetulus griseus	98-103	
11466425-3	2001	In the present study, we have compared the actions of retigabine on KCNQ2/3 currents with those on currents generated by other members of the KCNQ family (homomeric KCNQ1, KCNQ2, KCNQ3, and KCNQ4 channels) expressed in CHO cells and on the native M current in rat sympathetic neurons [thought to be generated by KCNQ2/3 channels (Wang et al., 1998)].	ezogabine	54-64	potassium voltage-gated channel subfamily KQT member 2	Cricetulus griseus	68-73	
11466425-4	2001	Retigabine produced a hyperpolarizing shift of the activation curves for KCNQ2/3, KCNQ2, KCNQ3, and KCNQ4 currents with differential potencies in the following order: KCNQ3 > KCNQ2/3 > KCNQ2 > KCNQ4, as measured either by the maximum hyperpolarizing shift in the activation curves or by the EC(50) values.	ezogabine	0-10	potassium voltage-gated channel subfamily KQT member 2	Cricetulus griseus	73-80	
11466425-4	2001	Retigabine produced a hyperpolarizing shift of the activation curves for KCNQ2/3, KCNQ2, KCNQ3, and KCNQ4 currents with differential potencies in the following order: KCNQ3 > KCNQ2/3 > KCNQ2 > KCNQ4, as measured either by the maximum hyperpolarizing shift in the activation curves or by the EC(50) values.	ezogabine	0-10	potassium voltage-gated channel subfamily KQT member 2	Cricetulus griseus	73-78	
11466425-4	2001	Retigabine produced a hyperpolarizing shift of the activation curves for KCNQ2/3, KCNQ2, KCNQ3, and KCNQ4 currents with differential potencies in the following order: KCNQ3 > KCNQ2/3 > KCNQ2 > KCNQ4, as measured either by the maximum hyperpolarizing shift in the activation curves or by the EC(50) values.	ezogabine	0-10	potassium voltage-gated channel subfamily KQT member 2	Cricetulus griseus	178-185	
11466425-4	2001	Retigabine produced a hyperpolarizing shift of the activation curves for KCNQ2/3, KCNQ2, KCNQ3, and KCNQ4 currents with differential potencies in the following order: KCNQ3 > KCNQ2/3 > KCNQ2 > KCNQ4, as measured either by the maximum hyperpolarizing shift in the activation curves or by the EC(50) values.	ezogabine	0-10	potassium voltage-gated channel subfamily KQT member 2	Cricetulus griseus	82-87	
23933653-0	2013	Discovery of a retigabine derivative that inhibits KCNQ2 potassium channels.	ezogabine	15-25	potassium voltage-gated channel subfamily KQT member 2	Cricetulus griseus	51-56	
23933653-1	2013	AIM: Retigabine, an activator of KCNQ2-5 channels, is currently used to treat partial-onset seizures.	ezogabine	5-15	potassium voltage-gated channel subfamily KQT member 2	Cricetulus griseus	33-38	
23933653-2	2013	The aim of this study was to explore the possibility that structure modification of retigabine could lead to novel inhibitors of KCNQ2 channels, which were valuable tools for KCNQ channel studies.	ezogabine	84-94	potassium voltage-gated channel subfamily KQT member 2	Cricetulus griseus	129-134	
23933653-11	2013	CONCLUSION: The retigabine derivative HN38 is a potent KCNQ2 inhibitor, which differs from XE991 in its influence on the channel kinetics.	ezogabine	16-26	potassium voltage-gated channel subfamily KQT member 2	Cricetulus griseus	55-60